Hepatocellular Carcinoma
Conditions
Brief summary
This is a Phase I, open-label, multi-center study to assess the safety, pharmacokinetics, and preliminary efficacy of GPC3-directed chimeric antigen receptor modified T cells injection (Ori-C101) in Advanced Hepatocellular Carcinoma(HCC).
Interventions
BIOLOGICALOri-C101
Hepatic arterial infusion
Sponsors
OriCell Therapeutics Co., Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
1. Confirmed pathologic or radiologic diagnosis of HCC ; 2. Tumor tissue GPC3 expression positive by immunohistochemistry(IHC) at the local laboratory (Tumor samples ≤1 years prior to ICF signature are acceptable), if no archived tumor tissue samples, tumor biopsy is required for GPC3 expression test; 3. Unresectable stage B (intermediate) or C (advanced) HCC according to the Barcelona Clinic Liver Cancer (BCLC) staging. If stage B, must have progressed after, or not be eligible for, surgical or locoregional therapy; 4. Received at least two prior line of systemic therapy (included but not limited to target therapy, immunotherapy or chemotherapy) with radiologic disease progression during or following systemic therapy; 5. Child-Pugh A or B7, no history of hepatic encephalopathy; 6. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 at the time of ICF signature; 7. Estimated life expectancy of minimum of 12 weeks; 8. Must have at least 1 target lesion
Exclusion criteria
1. Central nervous system metastatic disease, leptomeningeal disease, or metastatic cord compression; 2. Prior bone marrow or organ transplantation; 3. Have a history of another primary malignancy within 5 years prior to starting study treatment. Exceptions here are as follows: the disease under study; adequately treated basal or squamous cell carcinoma of the skin; cancer of the cervix in situ; 4. Active hepatitis B infection (If Hepatitis B surface antigen \[HBsAg\] or Hepatitis B core antibody \[HBcAb\] positive, then HBV-DNA must be \< 20 IU/mL, and HBsAg-positive patients should have been treated with antiviral therapies as per the local guidelines); 5. Positive hepatitis C (HCV) RNA, Human Immunodeficiency Virus (HIV) antibody, Cytomegalovirus(CMV) DNA or syphilis serology; 6. Have received prior cell-based therapies such as targeted GPC3 therapy, TCR-T therapy, CAR-T therapy; 7. Inadequate bone marrow reserve or organ function; 8. History or current evidence of any condition or disease that could confound the results of the study or, in the opinion of Investigator, is not in the best interest of the patient to participate. 9. Pregnant or Breast-feeding women.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Maximum tolerated dose of Ori-C101 | 1 year | The MTD is defined as the highest dose with an observed incidence of DLT in no more than one out of six patients treated at a particular dose level. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Objective Response Rate | 2 years | Objective response is defined as the participants with a partial response (PR) or better by the RECIST1.1 criteria. |
Countries
China
Outcome results
None listed